Bacteriophages against methicillin resistant Staphylococcus aureus strains




bacteriophage drugs, Staphylococсus aureus, antibiotic resistance


Staphylococcus aureus is one of the most common opportunistic pathogens that causes a variety of diseases, from minor skin infections to life-threatening sepsis, meningitis, pneumonia and a number of other diseases. Particular attention was paid to methicillin-resistant Staphylococcus aureus (MRSA) strains with multiple drug resistance. The purpose of this study is investigation of the sensitivity of clinical isolates of Staphylococcus aureus, including methicillin-resistant strains, to bacteriophage drugs and determination of possibility of using this agent for the treatment of staphylococcal infections. A number of classical and modern microbiological methods for the isolation and identification of Staphylococcus aureus: an indication of genes, responsible for antibiotic resistance (PCR analysis), determination of sensitivity to antibiotics (disc diffusion method) and bacteriophages (spot test, Gracia method, Appelman method) were used in the study. The susceptibility analysis of Staphylococcus aureus with presence and absence of mecA gene to the commercial bacteriophage product – “PYOFAG® BACTERIOPHAGE POLYVALENT” was performed. The results of the study showed that the total number of susceptible strains of bacteria was 95±0,2%. The use of investigational Bacteriophage drug for the treatment of furunculosis caused by MRSA has shown positive results. After one week of using the bacteriophage as monotherapy, the patient experienced regression of the clinical symptoms. For the period of use no adverse effects have been detected. Thus, the phage drugs using can become an important tool in the control of antibiotic-resistant strains, which cause a variety of infections in humans.


Adams MA. [Bacteriophages]. Moscow: Izda­tel­stvo inostrannoy literaturyi; 1961. Russian.

Demikhovskaya YeV. [MRSA – the famous and un­known methicillin-resistant s.aureus: resistance mecha­nisms, laboratory diagnostics, clinical picture and epide­miology]. Diseases and antibiotics. 2012;2(7):40-47. Russian.

Klymniuk SІ, Sytnyk ІO, Shyrobokov VP, et al. Editors: Klymniuk, S.І. and Shyrobokov V.P. [Praktychna mіkrobіolohіia: navchalnyi posіbnyk]. Vіnnytsia: Nova Knyha; 2018. Ukrainian.

Kotsar OV, Golubka OV, Masalova AA, et al. [Prevalence of methicillin-resistant staphylococci among bacterial carriers]. Theoretical and Experimental Medi­cine. 2016;4(73):23-26. Ukrainian.

[Order of the Ministry of Health of Ukraine No. 167 dated 05.04.2007 "On Approval of Guidelines "on Determination of Sensitivity of Microorganisms to Anti­bacterial Drugs"/ Order of the Ministry of Health of Ukraine No. 167 dated 05.04.2007]. (2007). Ukrainian.

Cassini A, Högberg L, Plachouras D, Quattroc­chi A, Hoxha A, Simonsen G et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. The Lancet Infectious Diseases. 2019;19(1):56-66. doi:

Chhibber S, Kaur T, Sandeep Kaur. Co-Therapy Using Lytic Bacteriophage and Linezolid: Effective Treatment in Eliminating Methicillin Resistant Staphylo­coccus aureus (MRSA) from Diabetic Foot Infections. PloS ONE. 2013;8(2):e56022. doi:

Dickey J, Perrot V. Adjunct phage treatment enhances the effectiveness of low antibiotic concentration against Staphylococcus aureus biofilms in vitro. PLOS ONE. 2019;14(1):e0209390. doi:

Dedrick R, Guerrero-Bustamante C, Garlena R, Russell D, Ford K, Harris K et al. Engineered bacterio­phages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nature Medicine. 2019;25(5):730-3; doi:

Capparelli R, Parlato M, Borriello G, Salvatore P, Iannelli D. Experimental Phage Therapy against Sta­phylococcus aureus in Mice. Antimicrobial Agents and Chemotherapy. 2007;51(8):2765-2773. doi:

Mariem N Mohammed-Ali, Nidham M. Jamal­ludeen. Isolation and Characterization of Bacteriophage against Methicillin Resistant Staphylococcus aureus. Journal of Medical Microbiology & Diagnosis. 2016;05(01). doi:

Miedzybrodzki R, Fortuna W, Weber-Dabrowska B, Górski A. Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment. Postepy higieny i medycyny doświadczalnej [Internet]. 2007;61:461-5.

Pendleton J, Gorman S, Gilmore B. Clinical rele­vance of the ESKAPE pathogens. Expert Review of Anti-infective Therapy. 2013;11(3):297-308; doi:

Leszczyński P, Weber-Dabrowska B, Kohutnic­ka M, et al. Successful eradication of methicillin-resistant Staphylococcus aureus (MRSA) intestinal carrier status in a healthcare worker-case report. Folia microbiologica. 2006;51(3):236-8. DOI:

Upshaw-Owens M, Bailey CA. Preventing hospi­tal-associated infection: mrsa. Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses. 2012;21(2):77-81.




How to Cite

Poniatovskyi V, Bondarchuk O, Prystupiuk M, Smikodub O, Shyrobokov V. Bacteriophages against methicillin resistant Staphylococcus aureus strains. Med. perspekt. [Internet]. 2020Dec.28 [cited 2024Apr.18];25(4):73-80. Available from: